559
Views
0
CrossRef citations to date
0
Altmetric
Original Article

The severity of hypogonadism symptoms and its risk factors among male employees of Tehran University of Medical Sciences

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 489-495 | Received 12 Jun 2018, Accepted 06 Oct 2018, Published online: 16 Jan 2019

Abstract

Objectives

The current study was conducted to examine the severity of hypogonadism symptoms and their risk factors among the male employees of Tehran University of Medical Sciences (TUMS).

Methods

This cross-sectional study was conducted on 80 male employees aged 40–60 years, with hypogonadism, at TUMS. The participants were selected through census sampling. The data collection tools included the demographic questionnaire and the Aging Male Symptoms (AMS) questionnaire. The participants first completed the demographic questionnaire and then the AMS questionnaire. SPSS statistical software version 22 (Chicago, IL) was used to analyze the data, and one-way ANOVA tests, Pearson’s correlation coefficient, and stepwise multivariate logistic regression were applied.

Results

Based on our findings, the mean overall score of hypogonadism symptoms was 41.71 ± 9.20. Based on Pearson’s correlation coefficient results, there was a statistically significant association between the severity of hypogonadism symptoms and age (p < .001). Furthermore, there were significant associations between the economic status, cigarette consumption and hours of sleep and the severity of hypogonadism symptoms (p < .001).

Conclusions

The current study’s results showed that certain factors can affect hypogonadism in males. Thus, it is important to reduce the severity of hypogonadism symptoms and to modify the factors related to this phenomenon.

Introduction

One of the important issues of today’s world is hypogonadism, which has recently caught the attention of the medical community [Citation1]. This important phenomenon occurs as a result of reduced androgen levels in men and plays an important role in their lives [Citation2]. In fact, hypogonadism is a transient phase, passing from one phase to another new phase in life [Citation3]. In addition to the physical issues, it affects social, sexual and psychological aspects too [Citation4,Citation5]. No significant age has been expressed for hypogonadism, but it usually occurs in middle age [Citation6–8]. In fact, the hormone testosterone plays an important role in male health, and as a condition in which reduced testosterone levels are seen, hypogonadism is associated with an increased serum level of glucose, total cholesterol and lipoproteins [Citation9]. Moreover, there is an inverse relationship between inflammatory markers such as highly sensitive C-reactive protein and reduced total testosterone levels [Citation10]. From the age of 40 onwards, testosterone levels annually fall by 0.4–2.6% [Citation1,Citation11]. Reduced testosterone levels cause a wide range of symptoms, including, erectile dysfunction, Lower Urinary Tract Symptoms (LUTS), depression, sleep disorders, reduced libido, hair loss, irritability, psychological disorders, hot flushes, etc. [Citation12–19]. Raised body fat percentage is another common symptom of hypogonadism, such that obese men and those with weak health are at greater risk of this urologic disorder [Citation17,Citation20]. The severity of hypogonadism symptoms may differ in different individuals. In the long run, these symptoms lead to diseases such as cardiovascular diseases, metabolic syndrome, osteoporosis, Alzheimer’s, sexual disorders, falls and early death [Citation21–24]. In the USA, approximately 5 to 10 million [Citation25], and in Iran, approximately 21.2% have been said to have this disorder among the general public [Citation26]. The results of some studies also indicate the high prevalence of hypogonadism in patients with benign prostatic hypertrophy (BPH) [Citation20], cardiac insufficiency [Citation19], and type II diabetes [Citation27]. Overall, based on an international study, a considerable number of males suffer from hypogonadism in which this disorder has not been diagnosed and treated [Citation28]. In spite of the importance of its early diagnosis and treatment, unfortunately, there is little data in this field in the scientific literature [Citation29]. Based on literature, cardiovascular risk factors such as body mass index (BMI), serum cholesterol and triglycerides can predict the incidence of urologic disorders in the following 25 years [Citation30,Citation31]. Nevertheless, the causes of hypogonadism have not been clearly stated yet either [Citation32]. However, given the population transition in Iran, many biological, psychological and social factors will affect the incidence of hypogonadism in the future.

Various studies have been conducted with respect to the risk factors of hypogonadism. Only the impact of few of these factors has been recognized, and most of these factors still have room for debate. In this regard, some studies have addressed the impact of factors such as age, BMI, cigarette consumption, educational status, employment, income, marital status, diabetes, and signs of hypogonadism [Citation1,Citation33–37]. Despite the aforementioned studies, there are still many doubts regarding the impact of each of these personal traits on hypogonadism. Given the problems threatening male health, the risk factors must be identified and dealt with to neutralize their effects. By detecting these factors, and through preventive measures, males can be safeguarded against the possible complications of this phenomenon [Citation38] and also reduce its associated healthcare costs. For example, many individuals with hypogonadism who have multiple associated diseases, increased waist circumference and obesity can benefit from lifestyle changes such as weight reduction as well as testosterone replacement therapy (TRT) [Citation39]. Multiple studies have indicated that the injection of testosterone undecanoate has led to a significant reduction in waist circumference and visceral fat, and has been introduced as an appropriate treatment of hypogonadism [Citation40]. Bearing in mind the significance of hypogonadism, the scarcity of data in this field in Iran, and the conflicting information present in earlier literature, we sought to estimate the prevalence of hypogonadism and its determinant factors in males employed at Tehran University of Medical Sciences (TUMS).

Materials and methods

This was a cross-sectional study. The statistical population consisted of all male employees aged 40–60 years employed at TUMS’ schools. The research sample included 80 individuals selected through census sampling. Among the 124 male employees falling in the desired age range, 115 were interested in participating in the study, of which 80 were eligible and were thus included. The inclusion criteria were age 40–60 years, consent to participate in the study, an AMS score of 27 or higher, absence of chronic diseases, psychological disorders and disabilities. The exclusion criteria were lack of inclination to participate in the study, having a chronic disease or psychological disorder over the course of the study, and incomplete filling of the AMS questionnaire [Citation38]. Sampling was done after the necessary licenses were obtained. Sampling was such that, upon visiting TUMS schools, qualified individuals would be briefed on the research and would then be invited to participate in the study. Consenting individuals were included in the study upon completing the informed consent form. First, the demographic questionnaire and later on the AMS questionnaire were completed for the purpose of screening and assessment of severity of symptoms in the participants. Moreover, this study was approved by TUMS Ethics Board under code no. 26288.

Questionnaire

The data collection tool consisted of two sections. The first was the demographic questionnaire which comprised 11 questions on age, marital status, educational status, economic status, cigarette consumption, hours of sleep during the day and night, and medical disorders. The second section of the questionnaire is the AMS questionnaire, which is a beneficial tool for assessing the severity of age-associated symptoms, and is repeatedly used by urologists and endocrinologists to diagnose and follow-up male hypogonadism [Citation11]. This tool contains 17 items in three physical (seven items), psychological (seven items), and sexual (five items) dimensions, and uses the Likert scale ranging from 1 to 5 (1 = none, 2 = mild, 3 = moderate, 4 = relatively severe, 5 = severe) based on the severity of symptoms. The scores of the dimensions range from 5 to 35. The overall AMS score is classified based on having no symptoms – with a score below 26, mild – at a score between 27 and 36, moderate – at a score between 37 and 49, and severe – at a score higher than 50 [41,42]. The validity and reliability of the AMS questionnaire has been approved in Iran with a Cronbach’s alpha of 0.7 [43].

Statistical analysis

Descriptive statistics (frequency, mean, standard deviation) and inferential statistics, including the independent t-test for comparing the mean scores of the hypogonadism dimensions in binomial variables, Pearson’s correlation for assessing the correlation between hypogonadism’s dimensions with age, and one-way ANOVA for comparing the mean scores of the hypogonadism dimensions for variables exceeding two states, were used. Eventually, those variables that had significant associations with the hypogonadism dimensions’ scores were entered into the stepwise multivariate regression. Data analysis was performed in SPSS Inc., Version 22 (Chicago, IL). The level of significance was considered at .05.

Results

The samples were 80 males, mostly of the 45–49-year-old age group that included 31 persons (38.8%). The demographic characteristics and severity of hypogonadism symptoms in the male employees are displayed in . shows the mean hypogonadism score for the population under study in different dimensions of the AMS questionnaire.

Table 1. Demographic characteristics of male employees at Tehran University of Medical Sciences.

Table 2. Central and peripheral indices related to the dimensions of severity of hypogonadism symptoms.

Pearson’s correlation coefficient showed that overall, there were significant associations between age and severity of hypogonadism symptoms in all the subscales (p < .001) ().

Table 3. Correlation coefficients between age and severity of hypogonadism symptoms among male employees of Tehran University of Medical Sciences’ schools.

The associations between the physical, psychological, sexual and overall hypogonadism scores and the male employees’ personal characteristics (education, economic status, cigarette consumption, number of hours of sleep) were examined using independent t-test and one-way ANOVA. The “educational status” variable was not significantly associated with the severity of hypogonadism symptoms in either of the dimensions (p > .05). However, the “economic status” (p < .001), cigarette consumption (p < .001), and the number of hours of sleep (p < .001) all had significant associations with the severity of hypogonadism symptoms ().

Table 4. Means and standard deviations of hypogonadism dimensions and personal traits among male employees of Tehran University of Medical Sciences’ schools, 2014.

Eventually, those variables that had significant associations with the overall score and dimensions of hypogonadism (age, economic status, cigarette consumption, number of hours of sleep) were entered into the multivariate regression model in stepwise fashion to examine their associations simultaneously.

shows that there is a significant association between the overall score of hypogonadism, and physical, psychological and sexual dimensions and age (p < .001). Moreover, there is a significant association between the physical dimension (p = .01), sexual dimension and overall hypogonadism score (p < .001) and the economic status. There were significant associations between the psychological dimension and number of hours of sleep (7 h or more) (p = .02), and between the overall hypogonadism score and the sexual dimension and cigarette consumption (p < .05).

Table 5. Results of stepwise regression for variables associated with hypogonadism among male employees of Tehran University of Medical Sciences’ schools, 2014.

Discussion

The current study has examined the association between demographic characteristics and severity of hypogonadism symptoms in male employees aged 40–60 years. Of the 80 participants, 26 (32.5%) had mild hypogonadism, 35 (43.75%) had moderate hypogonadism and 19 (23.75%) had severe hypogonadism. These results are not consistent with those of other studies. Xia et al. estimated the overall incidence of hypogonadism among middle–aged and elderly males aged over 45 years at 64.7%; mild, moderate, and severe hypogonadism were estimated at 58.1%, 30.9%, and 11%, respectively [Citation44]. Khosravi conducted a study on apparently healthy males aged 40–65 years, and found that 31.5%, 16.4%, and 3.6% had mild, moderate, and severe hypogonadism, respectively, and their mean score was 28.8 [45]. In our study, however, the frequency of males with severe hypogonadism was greater, which may be attributed to the difference in sampling, sample size, population under study and diagnostic criteria of hypogonadism. Therefore, it is not far from expectation to have a difference in prevalence too.

Here, the mean overall hypogonadism score was 41.71 ± 9.20, which is higher compared to the results of some other studies. In studies performed elsewhere, different figures have been estimated, e.g. in Iran, this estimate was 33.81 ± 11.36 [7], in China it was 31.2 ± 6.8 [44], and in Bulgaria it was 32.06 ± 7.87 [35]. The tool used in these studies was the same as the one used here, i.e. the AMS questionnaire. The differences in the overall hypogonadism scores between these studies and ours can also be associated with the sample size and difference in sampling methods.

The results of the regression indicated that the overall score and the subscales of severity of hypogonadism were positively associated with age; that is to say, the severity of symptoms increased with an increase in the men’s age. In our study, age was recognized as the most important predictor of severity of hypogonadism symptoms in male employees. Overall, a direct association has been observed between an increase in age and hypogonadism [Citation1,Citation26,Citation32,Citation33,Citation46–50], and the subscales of physical [Citation32], psychological [Citation51], and sexual [Citation44,Citation52,Citation53] symptoms in various similar studies. Given the fact that the levels of testosterone decrease with age in men, this issue is understandable. Reduced levels of androgen may cause disorders in physical, psychological and sexual performance [Citation54]. Nevertheless, in a study conducted by Khosravi in Iran, no significant association was observed between these variables [Citation45]. The difference between that study and ours can be explained by the difference in population under study and the number of samples.

We also observed an inverse significant association between economic status and the overall hypogonadism score and its physical and sexual subscales, such that a weak economic status was associated with an increase in the overall hypogonadism, and physical and sexual subscale scores. This type of association had been reported in many researches [Citation26,Citation48,Citation50,Citation53]. In fact, a good economic status can help deal with the changes brought about by hypogonadism and facilitate the access to healthcare services.

The current study’s results indicated an inverse significant association between hours of sleep (7 h or more) and severity of psychological symptoms in male employees with hypogonadism, findings which are consistent with those of Hirokawa et al. [Citation32]. In hypogonadism, sleep patterns change due to reduced levels of testosterone [Citation55]. Reduced androgen causes an overall reduction in quality and effectiveness of sleep, which are correlated with reduced mental health and psychological disorders [Citation56]. In the current study, a significant association was observed between cigarette consumption and severity of hypogonadism symptoms and the overall hypogonadism score, which is similar to the results of other research studies [Citation26,Citation45,Citation48,Citation57]. The effect of cigarette smoking has been indicated as a risk factor in many studies.

Moreover, consistent with the earlier studies conducted on Iranian males with hypogonadism [Citation57], there was no significant association between educational status and the severity of hypogonadism symptoms, which is in fact contrary to the findings of other studies [Citation26,Citation46]. The reason behind this difference may be that all the samples had been chosen from an academic environment.

Limitations

Given the study is cross-sectional in nature, we cannot develop causal relationships. Here, the symptoms were self-reported and serum hormonal levels were not measured. To control these circumstances, we used the AMS questionnaire. Another limitation of this study was the small sample size, which limits the generalization of findings. Furthermore, we could not examine the men’s BMI in this study; therefore, we recommend examining this important factor in future studies. Since all the samples were aged between 40 and 60 years, we recommend conducting the study on different age groups.

Conclusions

Given the rise in hypogonadism prevalence and the association between this and certain demographic factors, we recommend the delivery of appropriate educational programs by healthcare personnel and policy makers. Raising awareness and educating men about these symptoms and how to deal with them, and the application of methods to reduce the complications of hypogonadism, such as healthy nutrition, quitting smoking and physical activity are very important.

Acknowledgements

The authors thank all those who helped to conduct this research. This article is part of a thesis for a Master’s degree in Midwifery – with a special interest in Sociology – in Tehran University of Medical Sciences, under ethics code 26288.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was funded by Tehran University of Medical Sciences and Health Services [26288].

References

  • Liu CC, Wu WJ, Lee YC, et al. The prevalence of and risk factors for androgen deficiency in aging Taiwanese men. J Sex Med. 2009;6:936–946.
  • Lang PO, Samaras D, Samaras N. Testosterone replacement therapy in reversing “andropause”: what is the proof-of-principle? Rejuvenat Res. 2012;15:453–465.
  • Diamond J. The irritable male syndrome: understanding and managing the 4 key causes of depression and aggression. Emmaus (PA): Rodale; 2005.
  • Schwarz ER, Phan A, Willix RD, Jr. Andropause and the development of cardiovascular disease presentation—more than an epi-phenomenon. J Geriatr Cardiol: JGC. 2011;8:35–43.
  • Kaya E, Sikka SC, Kadowitz PJ, et al. Aging and sexual health: getting to the problem. Aging Male. 2017;20:65–80.
  • Fatusi A, Ijadunola K, Ojofeitimi E, et al. The influence of sociodemographic factors on awareness, knowledge and attitude toward andropause among health professionals in Ile-Ife, Nigeria. Aging Male. 2004;7:269–279.
  • Samipoor F, Pakseresht S, Rezasoltani P, et al. The association between hypogonadism symptoms with serum testosterone, FSH and LH in men. Aging Male. 2018;21:1–8.
  • Huhtaniemi IT. Andropause – lessons from the European male ageing study. Annales d'endocrinologie. 2014;75:128–131.
  • La Vignera S, Condorelli R, Vicari E, et al. Original immunophenotype of blood endothelial progenitor cells and microparticles in patients with isolated arterial erectile dysfunction and late onset hypogonadism: effects of androgen replacement therapy. Aging Male. 2011;14:183–189.
  • Shigehara K, Konaka H, Ijima M, et al. The correlation between highly sensitive C-reactive protein levels and erectile function among men with late-onset hypogonadism. Aging Male. 2016;19:239–243.
  • Panach-Navarrete J, Martínez-Jabaloyas JM; Group D-Ss. The influence of comorbidities on the aging males’ symptoms scale in patients with erectile dysfunction. Aging Male. 2017;20:146–152.
  • Saad F, Gooren LJ. Late onset hypogonadism of men is not equivalent to the menopause. Maturitas. 2014;79:52–57.
  • Tan R, Pu S, Culberson J. Role of androgens in mild cognitive impairment and possible interventions during andropause. Med Hypotheses. 2004;62:14–18.
  • Singh P. Andropause: current concepts. Indian J Endocrinol Metab. 2013;17:S621.
  • Jarzabek-Bielecka G, Pawlaczyk M. Aging and sexuality after menopause and andropause. Arch Perinat Med. 2012;4:206–209.
  • Cunningham G. Andropause or male menopause? Rationale for testosterone replacement therapy in older men with low testosterone levels. Endocr Pract. 2013;19:847–852.
  • Almehmadi Y, Yassin D-J, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18:186–194.
  • Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
  • Kulej-Lyko K, Majda J, von Haehling S, et al. Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure? Aging Male. 2016;19:221–230.
  • Kaplan SA, Lee JY, O’Neill EA, et al. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male. 2013;16:169–172.
  • Delev DP, Kostadinova II, Kostadinov ID, et al. Physiological and clinical characteristics of andropause. Folia Med (Plovdiv). 2009;51:15–22.
  • Samaras N, Samaras D, Lang P-O, et al. A view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes? Maturitas. 2013;74:213–219.
  • Blaya R, Thomaz LDGR, Guilhermano F, et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male. 2016;19:85–89.
  • Aslan Y, Guzel O, Balci M, et al. The impact of metabolic syndrome on serum total testosterone level in patients with erectile dysfunction. Aging Male. 2014;17:76–80.
  • Janot JM. Andropause: man's problem for the ages: male menopause currently affects up to 10 million American men, who can benefit from a customized exercise program. IDEA Fitness J. 2005;2:52–60.
  • Samizadeh E, Khosravi S, Samizadeh A, et al. Andropause: results of a comprehensive surveillance of prevalence and risk factors on 906 patients (ACoSPF-2010). Int J Adv Biol Biomed Res. 2014;2:535–544.
  • Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus – a series of case reports. Aging Male. 2015;18:164–168.
  • Trinick TR, Feneley MR, Welford H, et al. International web survey shows high prevalence of symptomatic testosterone deficiency in men. Aging Male. 2011;14:10–15.
  • Abootalebi M, Kargar M, Jahanbin I, et al. Knowledge and attitude about andropause among general physicians in Shiraz, Iran 2014. Int J Commun Based Nurs Midwif. 2016;4:27–35.
  • Carruthers M, Cathcart P, Feneley MR. Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes. Aging Male. 2015;18:217–227.
  • Yassin AA, Saad F, Haider A, et al. The role of the urologist in the prevention and early detection of cardiovascular disease. Arab J Urol. 2011;9:57–62.
  • Hirokawa K, Taniguchi T, Fujii Y, et al. Job demands as a potential modifier of the association between testosterone deficiency and andropause symptoms in Japanese middle-aged workers: a cross-sectional study. Maturitas. 2012;73:225–229.
  • Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metabol. 2002;87:589–598.
  • English KM, Pugh PJ, Parry H, et al. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clin Sci. 2001;100:661–665.
  • Kumanov P, Tomova A, Robeva R, et al. Influence of ageing and some lifestyle factors on male gonadal function: a study in Bulgaria. Andrologia. 2007;39:136–140.
  • Suzuki R, Allen NE, Appleby PN, et al. Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2009;20:811–824.
  • Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34:1669–1675.
  • Afsharnia E, Pakgohar M, Khosravi S, et al. Examining the effect of the computer-based educational package on quality of life and severity of hypogonadism symptoms in males. Aging Male. 2018;21:85–92.
  • Salman M, Yassin D-J, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20:45–48.
  • Wolf J, Keipert D, Motazedi H, et al. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. Aging Male. 2017;20:225–234.
  • Heinemann L, Zimmermann T, Vermeulen A, et al. A new ‘aging males’ symptoms' rating scale. Aging Male. 1999;2:105–114.
  • Afsharnia E, Pakgohar M, Khosravi S, et al. The quality of life and related factors in men with andropause. J Hayat. 2016;22:38–49.
  • Ardebili HE, Khosravi S, Larijani B, et al. Psychometric evaluation of the Persian version of the ‘aging male scales’ questionnaire. Int J Prevent Med. 2014;5:1178–1185.
  • Xia L, Zhang X-S, Ye Y-P, et al. Menopause-like symptoms among old and middle-aged males in Hefei area. Zhonghua Nan ke Xue = Nat J Androl. 2012;18:150–154.
  • Khosravi S. Explanation of life experience andropause in men and offering cultural-base health promotion’s intervention program and evaluation. Tehran: Tehran University of Medical Sciences and Health Services; 2015.
  • Lee A, Chu LW, Chong CY, et al. Relationship between symptoms of androgen deficiency and psychological factors and quality of life among Chinese men. Int J Androl. 2010;33:755–763.
  • Adebajo S, Odeyemi K, Oyediran M, et al. Knowledge and experiences of andropause among men in Lagos, Nigeria. West Afr J Med. 2007;26:106–112.
  • Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metabol. 2008;93:3870–3877.
  • Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self‐administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol. 2000;53:703–711.
  • Haring R, Ittermann T, Völzke H, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male. 2010;13:247–257.
  • Jankowska EA, Szklarska A, Lopuszanska M, et al. Age and social gradients in the intensity of aging males' symptoms in Poland. Aging Male. 2008;11:83–88.
  • Parazzini F, Chiaffarino F, Ricci E. The aging males' symptoms in the Italian population: results from a cross sectional study using the AMS scale. Arch Ital Urol Androl. 2006;78:87–91.
  • Huhtaniemi I, Makinen JI, Perheentupa A, et al. Late-onset hypogonadism in men. Experience from the Turku Male Ageing Study (TuMAS). Hormones (Athens). 2008;7:36–45.
  • Saalu L, Saalu L. Andropause (male menopause): valid concepts, fables and controversies. J Basic Med Sci. 2013;1:33–37.
  • Wittert G. The relationship between sleep disorders and testosterone in men. Asian J Androl. 2014;16:262–265.
  • Andersen ML, Tufik S. The effects of testosterone on sleep and sleep-disordered breathing in men: its bidirectional interaction with erectile function. Sleep Med Rev. 2008;12:365–379.
  • Khosravi S, Ardebili HE, Larijani B, et al. Are andropause symptoms related to depression? Aging Clin Exp Res. 2015;27:813–820.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.